iSpecimen Inc. (ISPC) Key Metrics
ISPC valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.3M
- Enterprise value
- −$1.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 5.0
- Price / book
- 1.8
- EV / EBITDA
- 0.4
- Dividend yield
- —
- Beta
- 1.65
ISPC key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsISPC returns How much profit the business earns on the capital it uses.
ISPC financial health Debt, liquidity and how easily interest is covered.
ISPC efficiency & capital use Working capital cycle and where the cash goes.
ISPC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ISPC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ISPC cash returned to shareholders
ISPC key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Share price at fiscal year-end | $10.40 | $106.20 | $400.80 | $1,100.00 | $6,248.00 | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −327.8% | −191.5% | −73.9% | −40.9% | −713.1% | — | — | — |
| Return on invested capital (ROIC) | — | −301.2% | −174.4% | −151.0% | — | — | — | — |
| Return on assets (ROA) | −111.1% | −99.3% | −54.9% | −34.0% | −42.7% | −89.3% | −114.5% | −132.2% |
| Return on tangible assets | −122.9% | −310.8% | −129.2% | −50.9% | −27.1% | −130.1% | −247.8% | −205.1% |
| Free cash flow margin | −219.9% | −89.3% | −106.3% | −86.6% | −105.1% | −17.0% | −96.7% | −84.4% |
| Financial health | ||||||||
| Total debt | $268,798 | $312,167 | $196,244 | $185,847 | $3.4M | $12.8M | $10.6M | $7.0M |
| Cash & short-term investments | $6.9M | $1.9M | $5.0M | $15.3M | $27.7M | $695,909 | $53,893 | $1.1M |
| Net debt | −$6.6M | −$1.6M | −$4.8M | −$15.1M | −$24.3M | $12.1M | $10.5M | $5.8M |
| Debt / equity | 0.09 | 0.09 | 0.02 | 0.01 | 0.11 | — | — | — |
| Debt / assets | 0.03 | 0.03 | 0.01 | 0.01 | 0.10 | 2.06 | 2.51 | 1.72 |
| Current ratio | 1.12 | 0.62 | 1.36 | 4.60 | 13.15 | 0.16 | 0.10 | 0.20 |
| Quick ratio | 1.12 | 0.61 | 1.36 | 4.60 | 14.35 | 0.16 | 0.10 | 0.20 |
| Interest coverage | — | -57.8 | -48.4 | -42.6 | -2.8 | -1.1 | -2.3 | -2.8 |
| Working capital | $723,284 | −$2.2M | $2.2M | $15.4M | $30.4M | −$18.7M | −$14.2M | −$9.0M |
| Invested capital | −$3.5M | $1.7M | $4.9M | $5.2M | $5.5M | −$15.2M | −$12.2M | −$12.6M |
| Tangible asset value | $2.1M | −$2.0M | $2.5M | $15.8M | $27.1M | −$29.9M | −$25.0M | −$19.9M |
| Net current asset value | $511,411 | −$2.5M | $2.2M | $15.4M | $27.0M | −$30.0M | −$25.4M | −$20.2M |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | — | — | — | — | $0 | $41 |
| Capex / revenue | 0.0% | 0.6% | 47.8% | 30.7% | 9.3% | 13.5% | 34.3% | 23.3% |
| Capex / depreciation | 0.00 | 0.02 | 2.24 | 2.65 | 1.03 | 1.35 | 2.32 | 2.19 |
| Stock-based compensation / revenue | 1.1% | 2.7% | 4.6% | 6.5% | 5.6% | 1.1% | 8.4% | 2.6% |
| R&D / revenue | 112.0% | 38.0% | 35.9% | 25.5% | 16.5% | 17.9% | 23.1% | 27.5% |
| SG&A / revenue | 341.9% | 136.1% | 117.6% | 119.0% | 84.4% | 61.6% | 99.2% | 79.8% |
| Efficiency | ||||||||
| Days sales outstanding | 141.2 | 86.1 | 126.2 | 154.5 | 118.7 | 83.6 | 102.7 | 85.2 |
| Days of inventory on hand | — | 3.1 | — | -115.2 | -208.8 | — | 8.8 | 7.3 |
| Days payables outstanding | 915.9 | 279.6 | 241.7 | 126.3 | 91.3 | 128.8 | 123.0 | 107.7 |
| Cash conversion cycle (days) | -770.4 | -190.3 | -115.5 | -86.9 | -181.4 | -45.1 | -11.6 | -15.2 |
| Receivables turnover | 2.58 | 4.24 | 2.89 | 2.36 | 3.08 | 4.36 | 3.55 | 4.28 |
| Payables turnover | 0.40 | 1.31 | 1.51 | 2.89 | 4.00 | 2.83 | 2.97 | 3.39 |
| Inventory turnover | — | 117.55 | — | — | — | — | 41.64 | 49.96 |
| Asset turnover | 0.20 | 0.74 | 0.49 | 0.34 | 0.53 | 1.57 | 1.04 | 1.09 |
| Average receivables | $746,467 | $2.2M | $3.4M | $4.4M | $3.6M | $1.9M | $1.2M | $1.0M |
| Average payables | $4.8M | $4.1M | $3.2M | $1.6M | $1.3M | $1.3M | $717,353 | $696,912 |
| Average inventory | $22,555 | $45,110 | — | −$1.5M | −$3.0M | — | $51,098 | $47,287 |
| Intangibles / total assets | 10.5% | 57.0% | 45.7% | 18.3% | 7.6% | 42.4% | 54.7% | 35.5% |
Computed from ISPC's annual financial statements (latest annual report filed April 1, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ISPC valuation and financial ratios
iSpecimen earned a return on equity of −327.8% in fiscal 2025. It ended the year with $0.3 million of debt and $6.9 million in cash and short-term investments, a net cash position of $6.6 million.
See the ISPC income statement, the ISPC chart for price history, or the ISPC stock overview for the latest quote and news.
ISPC key metrics FAQ
What is iSpecimen's return on equity?
iSpecimen's return on equity (ROE) was −327.8% in fiscal 2025: net income of -$10.5 million on average shareholders' equity of $3.2 million.
How much debt does iSpecimen have?
iSpecimen had total debt of $0.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.09 and more cash than debt.
What is iSpecimen's current ratio?
iSpecimen's current ratio was 1.12 at the end of fiscal 2025: current assets were 1.12 times current liabilities.